Lukas Flatz

7.5k citations

102 papers · 4.0k indexed · 2 hit papers · h-index 29

Impact in

Immunology top 1%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- interferon and immune responses
- T-cell and B-cell Immunology
Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- Inflammatory Biomarkers in Disease Prognosis

Papers in ⓘ

Oncology 67
- Cancer Immunotherapy and Biomarkers 38
- Cutaneous Melanoma Detection and Management 27
- CAR-T cell therapy research 24
Immunology 43
- Immunotherapy and Immune Responses 31
- Immune Cell Function and Interaction 13

Co-authors: Stefan Diem (14 shared papers)Martin Früh (7 shared papers)Wolfram Jochum (9 shared papers)Andreas Bergthaler (14 shared papers)Daniel D. Pinschewer (12 shared papers)Sabine Schmid (4 shared papers)Arnoud J. Templeton (1 shared paper)Diana Born (1 shared paper)
Journals: European Journal of Cancer (6 papers)Journal of Clinical Oncology (5 papers)Proceedings of the National Academy of Sciences (5 papers)Cancer Immunology Immunotherapy (5 papers)Journal of the European Academy of Dermatology and Venereology (3 papers)
Partner nations: Switzerland Germany United States

In The Last Decade

Lukas Flatz

94 papers receiving 3.9k citations

Hit Papers

align trajectories log scale

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab 2017 · 690 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 Lung Cancer
2015 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Lukas Flatz

Since Specialization

Citations

This map shows the geographic impact of Lukas Flatz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lukas Flatz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lukas Flatz more than expected).

Fields of papers citing papers by Lukas Flatz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lukas Flatz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lukas Flatz. The network helps show where Lukas Flatz may publish in the future.

Co-authors

The 25 scholars most cited alongside Lukas Flatz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lukas Flatz Line = papers co-authored together Lukas Flatz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 102 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab Lung Cancer ·Stefan Diem, Sabine Schmid, M. Krapf, Lukas Flatz, Diana Born, Wolfram Jochum, Arnoud J. Templeton, Martin Früh Hit paper breakdown →	2017	690
2	STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity Proceedings of the National Academy of Sciences ·Olivier Demaria, Aude De Gassart, Sanja Coso, Nicolas Gestermann, Jérémy Di Domizio, Lukas Flatz, Olivier Gaide, Olivier Michielin, Patrick Hwu, Tatiana V. Petrova, Fabio Martinon, Robert L. Modlin, Daniel E. Speiser, Michel Gilliet Hit paper breakdown →	2015	447
3	Interferons Direct Th2 Cell Reprogramming to Generate a Stable GATA-3+T-bet+ Cell Subset with Combined Th2 and Th1 Cell Functions Immunity ·Ahmed N. Hegazy, Caroline Peine, Caroline Helmstetter, Isabel Panse, Anja Fröhlich, Andreas Bergthaler, Lukas Flatz, Daniel D. Pinschewer, Andreas Radbruch, Max Löhning	2010	253
4	Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors European Journal of Cancer ·Omar Hasan Ali, Fiamma Berner, David Bomze, Mirjam Fässler, Stefan Diem, Antonio Cozzio, Markus Jörger, Martin Früh, Christoph Driessen, Tobias L. Lenz, Lukas Flatz	2018	143
5	Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection PLoS Pathogens ·Rami Sommerstein, Lukas Flatz, Mélissa M. Remy, Pauline Malinge, Giovanni Magistrelli, Nicolas Fischer, Sahin Mehmet, Andreas Bergthaler, Sébastien Igonet, Jan ter Meulen, Rigo Dorothée, Paolo Meda, Nadia Rabah, Bruno Coutard, Thomas A. Bowden, Paul‐Henri Lambert, Claire‐Anne Siegrist, Daniel D. Pinschewer	2015	126
6	Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA Proceedings of the National Academy of Sciences ·Lukas Flatz, Andreas Bergthaler, Juan Carlos de la Torre, Daniel D. Pinschewer	2006	126
7	Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses Proceedings of the National Academy of Sciences ·Alexander A. Navarini, Mike Recher, Karl S. Lang, Panco Georgiev, Susanne Meury, Andreas Bergthaler, Lukas Flatz, Jacques Billé, Régine Landmann, Bernhard Odermatt, Hans Hengartner, Rolf M. Zinkernagel	2006	114
8	Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity Nature Medicine ·Lukas Flatz, Ahmed N. Hegazy, Andreas Bergthaler, Admar Verschoor, Christina Claus, Marylise Fernandez, Luca Gattinoni, Susan Johnson, Florian Kreppel, Stefan Kochanek, Maries van den Broek, Andreas Radbruch, Frédéric Lévy, Paul‐Henri Lambert, Claire-Anne Siegrist, Nicholas P. Restifo, Max Löhning, Adrian F. Ochsenbein, Gary J. Nabel, Daniel D. Pinschewer	2010	106
9	Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer OncoImmunology ·Omar Hasan Ali, Stefan Diem, Eva Markert, Wolfram Jochum, Katrin Kerl, Lars E. French, Daniel E. Speiser, Martin Früh, Lukas Flatz	2016	99
10	Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden JAMA Oncology ·David Bomze, Omar Hasan Ali, Andrew Bate, Lukas Flatz	2019	98
11	T Cell-Dependence of Lassa Fever Pathogenesis PLoS Pathogens ·Lukas Flatz, Toni Rieger, Doron Merkler, Andreas Bergthaler, Tommy Regen, Mariann Schedensack, Lukas Bestmann, Admar Verschoor, Mario Kreutzfeldt, Wolfgang Brück, Uwe‐Karsten Hanisch, Stephan Günther, Daniel D. Pinschewer	2010	88
12	Daptomycin Is Highly Efficacious against Penicillin-Resistant and Penicillin- and Quinolone-Resistant Pneumococci in Experimental Meningitis Antimicrobial Agents and Chemotherapy ·Philippe Cottagnoud, Marc Pfister, Fernando Acosta, M. Cottagnoud, Lukas Flatz, Félix P. Kuhn, Hans‐Peter Müller, Armin Stucki	2004	85
13	Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC) Cancer Immunology Immunotherapy ·Sabine Schmid, Stefan Diem, Qiyu Li, M. Krapf, Lukas Flatz, Sebastian Leschka, Lotus Desbiolles, Dirk Klingbiel, Wolfram Jochum, Martin Früh	2018	79
14	BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors Journal of the American Academy of Dermatology ·Omar Hasan Ali, David Bomze, Sandra S. Ring, Fiamma Berner, Mirjam Fässler, Stefan Diem, Marie-Therese Abdou, Christoph M. Hammers, Shirin Emtenani, Anne Braun, Antonio Cozzio, Bernhard Mani, Wolfram Jochum, Enno Schmidt, Detlef Zillikens, Christian D. Sadik, Lukas Flatz	2019	76
15	Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression Proceedings of the National Academy of Sciences ·Andreas Bergthaler, Lukas Flatz, Ahmed N. Hegazy, Susan Johnson, Edit Horváth, Max Löhning, Daniel D. Pinschewer	2010	76
16	Impaired Antibody Response Causes Persistence of Prototypic T Cell–Contained Virus PLoS Biology ·Andreas Bergthaler, Lukas Flatz, Admar Verschoor, Ahmed N. Hegazy, Martin Holdener, Katja Fink, Bruno Eschli, Doron Merkler, Rami Sommerstein, Edit Horváth, Marylise Fernandez, André Fitsche, Beatrice M. Senn, J. Sjef Verbeek, Bernhard Odermatt, Claire‐Anne Siegrist, Daniel D. Pinschewer	2009	75
17	Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines Proceedings of the National Academy of Sciences ·Lukas Flatz, Rahul Roychoudhuri, Mitsuo Honda, Abdelali Filali‐Mouhim, Jean-Philippe Goulet, Nadia Kettaf, Min Lin, Mario Roederer, Elias K. Haddad, Rafick‐Pierre Sékaly, Gary J. Nabel	2011	72
18	Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–2036 European Journal of Cancer ·Claus Garbe, Ulrike Keim, Sara Gandini, Teresa Amaral, Alexander Katalinic, Bernd Hollezcek, Peter Martus, Lukas Flatz, Ulrike Leiter, David C. Whiteman	2021	70
19	Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies Clinical Infectious Diseases ·Omar Hasan Ali, David Bomze, Lorenz Risch, Silvio D. Brugger, Matthias Paprotny, Myriam Weber, Sarah Thiel, Lukas Kern, Werner C. Albrich, Philipp Köhler, Christian R. Kahlert, Pietro Vernazza, Philipp Bühler, Reto Schüpbach, Alejandro Gómez-Mejía, Alexandra Popa, Andreas Bergthaler, Josef Penninger, Lukas Flatz	2020	69
20	Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation Cell Reports ·Tom Hartwig, Pascale Zwicky, Bettina Schreiner, Nikhil Yawalkar, Phil F. Cheng, Alexander A. Navarini, Reinhard Dummer, Lukas Flatz, Curdin Conrad, Christoph Schlapbach, Burkhard Becher	2018	56

About Lukas Flatz

Lukas Flatz is a scholar working on Oncology, Immunology, Infectious Diseases, Molecular Medicine and Dermatology, having authored 102 papers that have together received 4.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (38 papers), Immunotherapy and Immune Responses (31 papers), Cutaneous Melanoma Detection and Management (27 papers), CAR-T cell therapy research (24 papers), Melanoma and MAPK Pathways (19 papers), Immune Cell Function and Interaction (13 papers), Viral Infections and Vectors (12 papers) and Viral Infections and Outbreaks Research (12 papers). The work is most often cited by research in Immunology (1.6k citations), Oncology (1.8k citations), Infectious Diseases (762 citations), Cancer Research (262 citations) and Epidemiology (592 citations). Lukas Flatz has collaborated with scholars based in Switzerland, Germany and United States. Frequent co-authors include Stefan Diem, Martin Früh, Wolfram Jochum, Andreas Bergthaler, Daniel D. Pinschewer, Sabine Schmid, Arnoud J. Templeton, Diana Born, Omar Hasan Ali and David Bomze. Their work appears in journals such as European Journal of Cancer, Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, Cancer Immunology Immunotherapy and Journal of the European Academy of Dermatology and Venereology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact